Spelling suggestions: "subject:"pancreatitis."" "subject:"pancreatitics.""
111 |
Co-ativador de transcrição gênica PGC-1 na pancreatite aguda / Transcriptional coactivator PGC-1 in acute pancreatitisLlimona, Flávia 01 March 2011 (has links)
PGC-1 é uma família de coativadores de fatores de transcrição que controlam a expressão de diversos genes envolvidos na homeostase energética celular. As isoformas PGC-1 e estão presente em tecidos com alto metabolismo oxidativo e são capazes de aumentar biogênese mitocondrial, -oxidação de ácidos graxos e gliconeogênese em resposta à exposição ao frio, jejum e exercício. Inicialmente mostramos que macrófagos in vitro aumentaram a expressão de PGC-1 após 1h da exposição à zymosan. Com isso, hipotetizamos que PGC-1 poderia ter sua expressão aumentada em resposta a um insulto bacteriano. Para verificar nossa hipótese analisamos a expressão de PGC-1 em um modelo de pancreatite aguda (PA), caracterizada por uma forte resposta inflamatória estéril inicial, seguida, após poucos dias, por translocação bacteriana intestinal e infecção disseminada. PA foi induzida por infusão retrograda de taurocolato de sódio (2,5%). Também analisamos PGC-1 em um modelo de sepse por ligadura e perfuração cecal (CLP), cujo conteúdo intestinal é depositado no peritôneo, causando infecção grave local e disseminada. Animais tratados com Imipenem durante 48h após PA também foram analisados, bem como a interferência de PGC-1 ASO no processo de fagocitose. A expressão de PGC-1 e foi medida por PCR quantitativo. PA foi confirmada pelo aumento da amilase sérica e a inflamação sistêmica ratificada por leucocitose. PGC1 aumentou no baço e nos leucócitos circulantes 48h após PA e no lavado peritoneal 24h após PA e CLP. No entanto, PGC1 diminuiu no baço 24h após PA. Tratamento com Imipenem diminuiu PGC- 1. A diminuição de PGC-1 após transfecção com ASO levou à redução do processo de fagocitose. Assim, concluímos que ocorre aumento de PGC-1 na presença de bactérias e esse aumento está relacionado com fagocitose / PGC1 is a family of transcriptional coactivators that controls the expression of several genes involved in cell energy homeostasis. PGC1 isoforms and are present in tissues with high oxidative metabolism and are able to enhance mitochondrial biogenesis, -oxidation of fatty acids and gluconeogenesis in response to exposure to cold, fasting and exercise. Initial results showed macrophages in vitro present increased PGC-1 expression after 1h exposure to zymosan. Thus, we hypothesized that PGC-1 could be up-regulated in response to bacterial insult. We tested our hypothesis following PGC-1 expression in an acute pancreatitis (AP) model, characterized initially by a strong sterile inflammatory response, followed, few days later, by bacterial intestinal translocation and disseminated infection. AP was induced by retrograde infusion of sodium taurocholate (2.5%). We also analysed PGC-1 in a model of sepsis by cecal ligation and puncture (CLP), whose intestinal content is deposited in the peritoneum, causing a severe local and disseminated infection. Animals submitted to PA and treated with Imipenem for 48 hours were also analyzed, as well as the interference of PGC-1 ASO in phagocytosis process. PGC-1 and expression were measured by quantitative PCR. AP was confirmed by increased blood amylase and the systemic inflammation was noted by leukocytosis after 48h. PGC1 was increased in spleen and circulating leukocytes 48h after AP and in peritoneal lavage 24h after AP and CLP. On the other hand, PGC1 was decreased in spleen 24h after AP induction. Imipenem treatment decreased PGC-1. The decreased of PGC-1 after ASO transfection led to a reduction of phagocytosis process. Thus, we conclude there is a PGC-1 increase in bacterial presence and this increase is related to phagocytosis
|
112 |
Pancreatite em pacientes com lúpus eritematoso sistêmico juvenil / Pancreatitis in juvenile systemic lupus erythematosus patientsMarques, Victor Leonardo Saraiva 14 November 2017 (has links)
Introdução: Pancreatite é uma manifestação incomum e com risco de vida no lúpus eritematoso sistêmico juvenil (LESJ). Objetivo: Estudar a classificação da pancreatite em pacientes com LESJ de acordo com as definições do Grupo Internacional de Estudos de Pancreatite Pediátrica (INSPPIRE) e determinar prevalência geral, características clínicas, alterações laboratoriais e prognóstico do primeiro episódio. Métodos: Um estudo de coorte retrospectivo multicêntrico incluiu 852 pacientes com LESJ estudados em 10 serviços de referência terciária de reumatologia pediátrica. Resultados: Pancreatite foi diagnosticada em 22 de 852 (2.6%) pacientes com LESJ. Foram classificados como pancreatite aguda em 20 (91%), pancreatite aguda recorrenteem 2 (9%), e nenhum deles apresentou pancreatite crônica. Nenhum deles tinha cálculos biliares, pancreatite traumática, ou relatou o uso de álcool e/ou tabagismo. A comparação dos pacientes com pancreatite (primeiro episódio) e sem esta complicação, revelou uma menor duração da doença [1 (0-10) vs. 4 (0-23) anos, P < 0,0001] e maior mediana do Índice de Atividade de Doença do LES 2000 [21 (0-41) vs. 2 (0-45), P < 0,0001]. A frequência de febre (P < 0,0001), perda de peso (P < 0,0001), serosite (P < 0,0001), nefrite (P < 0,0001), hipertensão arterial (P < 0,0001), insuficiência renal aguda (P < 0,0001), síndrome de ativação macrofágica (P < 0,0001), e morte (P=0,001) foram maiores em pacientes com pancreatite. A freqüência de metilprednisolona endovenosa (P < 0,0001) e a mediana da prednisona [55 (15-60) vs. 11 (1-90) mg/dia, P < 0,0001] foram significantemente maiores em pacientes com pancreatite. Dois pacientes apresentavam pancreatite aguda recorrente com dois episódios distintos, com intervalo sem dor entre os dois episódios de 1 e 4 anos. Conclusão: Este foi o primeiro estudo classificando a pancreatite usando as definições do Grupo Internacional de Estudos de Pancreatite Pediátrica em pacientes com LESJ mostrando uma predominância da pancreatite aguda associado ao tratamento com glicocorticóide e atividade grave da doença / Introduction: Pancreatitis is a rare and a life-threatening systemic lupus erythematosus (SLE) manifestation in childhood-onset SLE (cSLE). Objective: To study the classification of pancreatitis in cSLE according to the International Study Group of Pediatric Pancreatitis and determine the overall prevalence, clinical features, laboratory, and first episode outcomes. Methods: A multicenter cohort study in 10 pediatric rheumatology centers, included 852 patients with cSLE. Results: Pancreatitis was diagnosed in 22 of 852 (2.6%) patients with cSLE. It was classified as acute pancreatitis in 20 (91%), acute recurrent pancreatitis in 2 (9%), and none of them had chronic pancreatitis. None of them had gallstones, traumatic pancreatitis, or reported alcohol/tobacco use. The comparison of patients with pancreatitis (first episode) and without this complication revealed a shorter disease duration [1 (0-10) vs. 4 (0-23) anos, P<0.0001] and higher median of Systemic Lupus Erythematosus Disease Activity Index 2000 [21 (0-41) vs. 2 (0-45), P < 0.0001]. The frequencies of fever (P < 0.0001), weight loss (P < 0.0001), serositis (P < 0.0001), nephritis (P < 0.0001), arterial hypertension (P < 0.0001), acute renal failure (P < 0.0001), macrophage activation syndrome (P < 0.0001), and death (P=0.001) were also higher in patients with pancreatitis. The frequencies of intravenous methylprednisolone use (P < 0.0001) and the median of prednisone dose [55 (15-60) vs. 11 (1-90) mg/dia, P<0.0001] were significantly higher in patients with pancreatitis. Of note, the 2 patients with acute recurrent pancreatitis had 2 episodes, with pain free interval of 1 and 4 years. Conclusions: This was the first study characterizing pancreatitis using the International Study Group of Pediatric Pancreatitis standardized definitions in patients with cSLE showing that the predominant form is acute pancreatitis seen in association with glucocorticoid treatment and active severe disease
|
113 |
Mecanismos de ação da solução salina hipertônica na pancreatite aguda experimental / Mechanisms of action of hypertonic saline solution in experimental acute pancreatitisCoelho, Ana Maria de Mendonça 17 March 2010 (has links)
INTRODUÇÃO: A pancreatite aguda (PA) grave é um processo inflamatório do pâncreas caracterizado por alterações hemodinâmicas e resposta inflamatória sistêmica com altos níveis de mortalidade. A ativação inapropriada intrapancreática das enzimas pancreáticas desempenha papel importante no desencadeamento dos mecanismos inflamatórios responsáveis pelas manifestações locais e sistêmicas da doença. Em trabalho anterior observamos redução significativa da mortalidade após administração de solução salina hipertônica em ratos, através de redução das alterações hemodinâmicas e da resposta inflamatória sistêmica, mas os efeitos da solução salina hipertônica na ativação das enzimas pancreáticas e na própria lesão pancreática não foram estudados. O objetivo deste estudo foi avaliar se o mecanismo de ação da solução salina hipertônica, reduzindo a gravidade da pancreatite aguda em ratos, ocorre devido à redução da intensidade da lesão pancreática e/ou à redução da resposta inflamatória sistêmica e seus efeitos. MÉTODOS: Foi utilizado um modelo experimental de pancreatite aguda grave através da injeção intraductal de taurocolato de sódio a 2,5%. Cento e quarenta e dois ratos Wistar machos foram divididos em quatro grupos: Controle (animais que não foram submetidos à indução da PA), Grupo ST (animais que não receberam tratamento após a indução da PA), Grupo SSF (animais que receberam 34ml/Kg de solução salina fisiológica de NaCl 0,9% por via endovenosa, 1 hora após a indução da PA) e grupo SSH (animais que receberam 4ml/Kg de solução salina hipertônica de NaCl 7,5% por via endovenosa, 1 hora após a indução da PA). Após 2, 12 e 24 horas da indução da PA os animais foram sacrificados e os materiais foram coletados para análise. Foram efetuadas a quantificação do volume de líquido ascítico e as determinações no líquido ascítico e no soro dos peptídeos liberados na ativação do tripsinogênio (TAP) e da atividade da amilase. No tecido pancreático foram realizadas as análises da peroxidação lipídica (MDA), da atividade da mieloperoxidase (MPO) e a análise histológica. Os níveis de citocinas (TNF-, IL-6 e IL-10) foram analisados no líquido ascítico, soro e tecido pancreático. RESULTADOS: Os níveis de TAP e amilase no líquido ascítico e soro, de MDA e MPO no tecido pancreático e a análise histológica mostraram resultados iguais nos três grupos de animais que foram submetidos a PA (ST, SSF e SSH). Observamos redução do volume de líquido ascítico e dos níveis de TNF- , IL-6 e IL-10 no líquido ascítico, soro e tecido pancreático nos animais nos quais foi administrada solução salina hipertônica (grupo SSH) quando comparados com os animais tratados com solução salina fisiológica (grupo SSF) e os animais sem tratamento (grupo ST) (p<0,05). CONCLUSÕES: A administração de solução salina hipertônica (NaCl 7,5%) na pancreatite aguda experimental foi capaz de reduzir a resposta inflamatória local e sistêmica, sem modificar contudo a intensidade das lesões pancreáticas. / INTRODUCTION: Severe acute pancreatitis (AP) is characterized by hemodynamic alterations and systemic inflammatory response leading to a high mortality rate. In AP the inappropriate activation of pancreatic enzymes plays an important role in pancreas autodigestion and in the inflammatory mechanisms responsible for the systemic response of the disease. In a previous study, we have demonstrated that hypertonic saline solution infusion significantly reduced mortality in experimental AP through an improvement in the hemodynamic conditions and by an antiinflammatory response, but its effects on the pancreatic lesions were not evaluated. The aim of the present study was to evaluate if the hypertonic saline solution reduces mortality in AP through a local effect attenuating the pancreatic lesion and/or by reducing the systemic inflammatory response syndrome (SIRS). METHODS: An experimental model of severe AP by injection of 0.5ml of 2.5% sodium taurocholate into the pancreatic duct was utilized. A hundred and forty two male Wistar rats were divided into 4 groups: C (control, without AP), ST (no treated AP), SSF (animals received 34ml/kg of normal saline solution of NaCl 0.9% IV, 1 hour after AP), and SSH (animals received 4ml/Kg of hypertonic saline solution of NaCl 7.5% IV, 1 hour after AP). After 2, 12 and 24 hours of induction of AP volume of ascitic fluid, trypsinogen activation peptides (TAP) levels and amylase activity in ascitic fluid and serum were determined. Pancreatic lipid peroxidation (MDA), myeloperoxidase (MPO) activity, and pancreatic histology were analysed 2 and 24 hours after AP. TNF-, IL-6, and IL-10 levels in ascitic fluid, serum, and pancreatic tissue were also analyzed. RESULTS: There were no significant differences in TAP levels and amylase activity in the ascitic fluid and serum in animals of groups ST, SSF and SSH. No differences in pancreatic MPO, MDA and histological score were observed among these three groups with AP. In the SSH group it was observed a significant decrease in volume of ascitic fluid and inflammatory cytokines levels (TNF-, IL-6, and IL-10) in ascitic fluid, serum, and pancreatic tissue when compared to ST and SSF groups (p<0.05). CONCLUSIONS: These findings suggest that hypertonic saline solution decreases local and systemic inflammatory response in acute pancreatitis without changing the intensity of the pancreatic lesions.
|
114 |
Alterações cardíacas na pancreatite aguda experimental / Myocardial alterations in experimental acute pancreatitisMeyer, Alberto Luiz Monteiro 01 August 2013 (has links)
Introdução: Vários são os mecanismos envolvidos no desenvolvimento da resposta local e sistêmico na pancreatite aguda. O sistema cardiovascular pode ser afetado durante todo o curso clínico da pancreatite aguda. O objetivo deste estudo foi avaliar a produção local de citocinas pelo miocárdio, assim como, as alterações funcionais e histológicas do miocárdio na pancreatite aguda grave. Métodos: Os animais foram divididos em três grupos: Grupo 1: controle; Grupo 2: controle operado; Grupo 3: pancreatite aguda grave. Foram medidos os níveis séricos de amilase e de citocinas (TNF-alfa IL-6 e IL-10), expressão de RNAm de TNF-alfa, IL-6 e TGF-beta e ecocardiograma com avaliação da função cardíaca. Alterações do tecido cardíaco foram analisadas pelo exame histológico. Resultados: Os níveis séricos de TNF-alfa e IL-10 foram significativamente maiores no grupo pancreatite aguda 2h. Os níveis de RNAm de IL-6 do grupo pancreatite aguda 2h foram estatisticamente superiores. Os níveis de RNAm do TNF-alfa do grupo controle operado e pancreatite aguda 2h foram estatisticamente menores. Mudanças significativas no diâmetro do ventrículo esquerdo foram encontradas nos grupos pancreatite aguda 2h e 12h. Houve alterações estatísticas para a degeneração vacuolar, picnose e perda de núcleo, e os linfócitos. Conclusão: Encontramos alterações cardíacas e histológicas compatíveis com o processo inflamatório desencadeado por pancreatite aguda grave com o incremento da produção de citocinas pelo miocárdio / Background: Several mechanisms are involved in the development of the local and systemic response in acute pancreatitis. Cardiovascular system may be affected throughout the clinical course of acute pancreatitis. The aim was to evaluate local myocardial cytokine production, as well as, functional and histological myocardial alterations in severe acute pancreatitis. Methods: The animals were divided into three groups: Group 1: control; Group 2: sham; Group 3: severe acute pancreatitis. Echocardiographic assessment of cardiac function, serum levels of amylase and cytokines (TNF-alfa, IL-6 and IL-10), and mRNA expression of TNF-alfa, IL-6 and TGF-beta were measured. Myocardial tissue alterations were analysed by histological examination. Results: The serum TNF-alfa, and IL-10 levels were significant higher in acute pancreatitis 2h group. The mRNA IL-6 levels from acute pancreatitis 2h group were statistically higher. The mRNA TNF-alfa levels from sham group and acute pancreatitis 2h group were statistically lower. Significant changes in the left ventricular diameter were found in acute pancreatitis 2h and 12h groups. There were statistical changes for vacuolar degeneration, picnosis and loss of nucleus, and lymphocytes. Conclusion: We found cardiac and histological changes compatible with the inflammatory process triggered by severe acute pancreatitis with the promotion of local myocardial cytokine production
|
115 |
Co-ativador de transcrição gênica PGC-1 na pancreatite aguda / Transcriptional coactivator PGC-1 in acute pancreatitisFlávia Llimona 01 March 2011 (has links)
PGC-1 é uma família de coativadores de fatores de transcrição que controlam a expressão de diversos genes envolvidos na homeostase energética celular. As isoformas PGC-1 e estão presente em tecidos com alto metabolismo oxidativo e são capazes de aumentar biogênese mitocondrial, -oxidação de ácidos graxos e gliconeogênese em resposta à exposição ao frio, jejum e exercício. Inicialmente mostramos que macrófagos in vitro aumentaram a expressão de PGC-1 após 1h da exposição à zymosan. Com isso, hipotetizamos que PGC-1 poderia ter sua expressão aumentada em resposta a um insulto bacteriano. Para verificar nossa hipótese analisamos a expressão de PGC-1 em um modelo de pancreatite aguda (PA), caracterizada por uma forte resposta inflamatória estéril inicial, seguida, após poucos dias, por translocação bacteriana intestinal e infecção disseminada. PA foi induzida por infusão retrograda de taurocolato de sódio (2,5%). Também analisamos PGC-1 em um modelo de sepse por ligadura e perfuração cecal (CLP), cujo conteúdo intestinal é depositado no peritôneo, causando infecção grave local e disseminada. Animais tratados com Imipenem durante 48h após PA também foram analisados, bem como a interferência de PGC-1 ASO no processo de fagocitose. A expressão de PGC-1 e foi medida por PCR quantitativo. PA foi confirmada pelo aumento da amilase sérica e a inflamação sistêmica ratificada por leucocitose. PGC1 aumentou no baço e nos leucócitos circulantes 48h após PA e no lavado peritoneal 24h após PA e CLP. No entanto, PGC1 diminuiu no baço 24h após PA. Tratamento com Imipenem diminuiu PGC- 1. A diminuição de PGC-1 após transfecção com ASO levou à redução do processo de fagocitose. Assim, concluímos que ocorre aumento de PGC-1 na presença de bactérias e esse aumento está relacionado com fagocitose / PGC1 is a family of transcriptional coactivators that controls the expression of several genes involved in cell energy homeostasis. PGC1 isoforms and are present in tissues with high oxidative metabolism and are able to enhance mitochondrial biogenesis, -oxidation of fatty acids and gluconeogenesis in response to exposure to cold, fasting and exercise. Initial results showed macrophages in vitro present increased PGC-1 expression after 1h exposure to zymosan. Thus, we hypothesized that PGC-1 could be up-regulated in response to bacterial insult. We tested our hypothesis following PGC-1 expression in an acute pancreatitis (AP) model, characterized initially by a strong sterile inflammatory response, followed, few days later, by bacterial intestinal translocation and disseminated infection. AP was induced by retrograde infusion of sodium taurocholate (2.5%). We also analysed PGC-1 in a model of sepsis by cecal ligation and puncture (CLP), whose intestinal content is deposited in the peritoneum, causing a severe local and disseminated infection. Animals submitted to PA and treated with Imipenem for 48 hours were also analyzed, as well as the interference of PGC-1 ASO in phagocytosis process. PGC-1 and expression were measured by quantitative PCR. AP was confirmed by increased blood amylase and the systemic inflammation was noted by leukocytosis after 48h. PGC1 was increased in spleen and circulating leukocytes 48h after AP and in peritoneal lavage 24h after AP and CLP. On the other hand, PGC1 was decreased in spleen 24h after AP induction. Imipenem treatment decreased PGC-1. The decreased of PGC-1 after ASO transfection led to a reduction of phagocytosis process. Thus, we conclude there is a PGC-1 increase in bacterial presence and this increase is related to phagocytosis
|
116 |
Pancreatite em pacientes com lúpus eritematoso sistêmico juvenil / Pancreatitis in juvenile systemic lupus erythematosus patientsVictor Leonardo Saraiva Marques 14 November 2017 (has links)
Introdução: Pancreatite é uma manifestação incomum e com risco de vida no lúpus eritematoso sistêmico juvenil (LESJ). Objetivo: Estudar a classificação da pancreatite em pacientes com LESJ de acordo com as definições do Grupo Internacional de Estudos de Pancreatite Pediátrica (INSPPIRE) e determinar prevalência geral, características clínicas, alterações laboratoriais e prognóstico do primeiro episódio. Métodos: Um estudo de coorte retrospectivo multicêntrico incluiu 852 pacientes com LESJ estudados em 10 serviços de referência terciária de reumatologia pediátrica. Resultados: Pancreatite foi diagnosticada em 22 de 852 (2.6%) pacientes com LESJ. Foram classificados como pancreatite aguda em 20 (91%), pancreatite aguda recorrenteem 2 (9%), e nenhum deles apresentou pancreatite crônica. Nenhum deles tinha cálculos biliares, pancreatite traumática, ou relatou o uso de álcool e/ou tabagismo. A comparação dos pacientes com pancreatite (primeiro episódio) e sem esta complicação, revelou uma menor duração da doença [1 (0-10) vs. 4 (0-23) anos, P < 0,0001] e maior mediana do Índice de Atividade de Doença do LES 2000 [21 (0-41) vs. 2 (0-45), P < 0,0001]. A frequência de febre (P < 0,0001), perda de peso (P < 0,0001), serosite (P < 0,0001), nefrite (P < 0,0001), hipertensão arterial (P < 0,0001), insuficiência renal aguda (P < 0,0001), síndrome de ativação macrofágica (P < 0,0001), e morte (P=0,001) foram maiores em pacientes com pancreatite. A freqüência de metilprednisolona endovenosa (P < 0,0001) e a mediana da prednisona [55 (15-60) vs. 11 (1-90) mg/dia, P < 0,0001] foram significantemente maiores em pacientes com pancreatite. Dois pacientes apresentavam pancreatite aguda recorrente com dois episódios distintos, com intervalo sem dor entre os dois episódios de 1 e 4 anos. Conclusão: Este foi o primeiro estudo classificando a pancreatite usando as definições do Grupo Internacional de Estudos de Pancreatite Pediátrica em pacientes com LESJ mostrando uma predominância da pancreatite aguda associado ao tratamento com glicocorticóide e atividade grave da doença / Introduction: Pancreatitis is a rare and a life-threatening systemic lupus erythematosus (SLE) manifestation in childhood-onset SLE (cSLE). Objective: To study the classification of pancreatitis in cSLE according to the International Study Group of Pediatric Pancreatitis and determine the overall prevalence, clinical features, laboratory, and first episode outcomes. Methods: A multicenter cohort study in 10 pediatric rheumatology centers, included 852 patients with cSLE. Results: Pancreatitis was diagnosed in 22 of 852 (2.6%) patients with cSLE. It was classified as acute pancreatitis in 20 (91%), acute recurrent pancreatitis in 2 (9%), and none of them had chronic pancreatitis. None of them had gallstones, traumatic pancreatitis, or reported alcohol/tobacco use. The comparison of patients with pancreatitis (first episode) and without this complication revealed a shorter disease duration [1 (0-10) vs. 4 (0-23) anos, P<0.0001] and higher median of Systemic Lupus Erythematosus Disease Activity Index 2000 [21 (0-41) vs. 2 (0-45), P < 0.0001]. The frequencies of fever (P < 0.0001), weight loss (P < 0.0001), serositis (P < 0.0001), nephritis (P < 0.0001), arterial hypertension (P < 0.0001), acute renal failure (P < 0.0001), macrophage activation syndrome (P < 0.0001), and death (P=0.001) were also higher in patients with pancreatitis. The frequencies of intravenous methylprednisolone use (P < 0.0001) and the median of prednisone dose [55 (15-60) vs. 11 (1-90) mg/dia, P<0.0001] were significantly higher in patients with pancreatitis. Of note, the 2 patients with acute recurrent pancreatitis had 2 episodes, with pain free interval of 1 and 4 years. Conclusions: This was the first study characterizing pancreatitis using the International Study Group of Pediatric Pancreatitis standardized definitions in patients with cSLE showing that the predominant form is acute pancreatitis seen in association with glucocorticoid treatment and active severe disease
|
117 |
Diminuição dos níveis de quimiocinas no tecido cardíaco de ratos idosos submetidos ao modelo de pancreatite aguda grave: um novo mecanismo cardioprotetor durante a inflamação sistêmica / Decreased gene expression of chemokines in the heart tissue of aged rats subjected to model of severe acute pancreatitis: a new mechanism of heart protection during systemic inflammationRizia Callou Amaral 14 July 2016 (has links)
A pancreatite aguda (PA) é uma doença que frequentemente está associada a uma inflamação local e sistêmica não controlada que é responsável pela alta morbidade e mortalidade desta doença. Independentemente do mecanismo inicial, o processo inflamatório ocorre após uma lesão nas células acinares, levando ao recrutamento de células inflamatórias que produzem citocinas e quimiocinas que são capazes de desempenhar um papel importante na patogênese dessa doença. A inflamação pancreática induz distúrbios profundos na homeostase levando ao dano tecidual em outros órgãos, tais como o intestino e o pulmão. Por outro lado, órgãos como o cérebro têm mecanismos estruturais e celulares de proteção contra a inflamação. Tem sido descrito, que pacientes com insuficiência cardíaca apresentam lesão cardíaca, levando a produção de citocinas pró-inflamatórias, ativação de células T e do sistema complemento. Além da cascata inflamatória, durante todo o estágio da PA o sistema cardiovascular pode sofrer alterações cardíacas e histológicas compatíveis com o processo inflamatório desencadeado pela PA. A intensidade da inflamação sistêmica devido à PA é semelhante em ratos jovens e idosos, porém, a duração da inflamação sistêmica parece ser muito maior nos idosos. A idade avançada é considerada um fator prognóstico independente para um pior prognóstico na PA, mas os mecanismos envolvidos não são totalmente compreendidos. Decidimos analisar a expressão gênica de diversas citocinas, quimiocinas e fatores de crescimento no coração de ratos idosos e jovens submetidos ao modelo animal de PA, com o objetivo de investigar os efeitos da inflamação sistêmica no coração e determinar se esses efeitos sofrem algum tipo de modificação durante a senilidade. Ratos jovens e idosos foram submetidos à PA utilizando-se ácido taurocólico 2,5% e, após 11 horas, o tecido cardíaco foi coletado para histologia e para a extração de RNA. A determinação do RNAm de citocinas e quimiocinas foi feita através do PCR Array. Como resultado, a expressão das interleucinas IL-6 E IL-10, e as quimiocinas CCL7 e CCL19 nos ratos idosos com PA foi menor do que nos ratos jovens com PA. Entretanto, os níveis de CXCL3 e CCL20 aumentaram nos idosos com PA. A expressão de CCL20 e CCL19 foi significativamente alta em ambos os grupos jovens e idosos com PA quando comparados com seus respectivos controles. Nos idosos com PA houve uma redução na expressão de CXCL1, CCL1, CCL11 e IL-10 comparados com seus controles, já entre os grupos saudáveis os idosos expressaram mais do que os jovens. Na análise histológica, a infiltração dos neutrófilos foi significativamente maior no tecido cardíaco dos ratos jovens e idosos com PA, comparado com seus controles. Esse estudo indica que a inflamação sistêmica pode mostrar características únicas para diferentes órgãos do corpo, e a diminuição da expressão gênica de algumas quimiocinas no tecido cardíaco de ratos mais velhos com PA pode sugerir um possível mecanismo cardioprotetor em animais mais velhos / Acute pancreatitis (AP) is a disease frequently associated with uncontrolled local and systemic inflammation that is responsible for the morbidity and mortality of this disease. Regardless of the initial mechanism, the inflammatory process is triggered by injury to the pancreatic acinar cells, leading to recruitment of inflammatory cell that produce cytokines and chemokines, which play an important role in the pathogenesis of this disease. Pancreatic inflammation induces profound disturbances in homeostasis, leading to tissue injury in other organs such as the intestine and lung. On the other hand, organs such as the brain have structural and cellular mechanisms of protection against inflammation. It has been described that patients with heart failure exhibit cardiac injury, leading to the production of pro-inflammatory cytokines, activation of T cells and activation of the complement system. In addition to inflammatory cascade during all stage of the PA, the cardiovascular system may suffer cardiac and histological changes compatible with inflammatory process triggered by the AP. The intensity of systemic inflammation associated with AP is similar in young and old rats, however, the duration of systemic inflammation is much longer in older animals. Advanced age is considered to be an independent prognostic factor for a poorer prognosis in AP, but the mechanisms involved are not fully understood. We analyzed the gene expression of several cytokines, chemokines and growth factors in young and aged rats hearts in an animal model of AP to investigate the effects of systemic inflammation on the heart, and to determine whether the effects are modified with age. Young and old rats were subjected to AP using taurocholic acid (2.5%) and after 11 hours, the cardiac tissue was collected to histology and RNA extraction. The determination of mRNA of cytokines and chemokines was performed by PCR array. The expression of interleukins IL-6 and IL-10 and the chemokines CCL7 and CCL19 in the aged AP rats was lower than young AP rats. However, CXCL3 and CCL20 levels showed opposite results, with increased levels in the aged AP group. The expression of CCL20 and CCL19 was greater in both young and aged AP rats compared with their respective controls. In aged AP rats there were a reduction in the expression of CXCL1, CCL1, CCL11 and IL-10 compared to their controls, and among healthy groups, the elderly rats expressed more than the young rats. In histological analysis, the neutrophils infiltration was significantly higher in the heart tissue of AP rats, both young and old, compared with their controls. This study indicates that systemic inflammation may show unique features for different organs in the body and decreased gene expression of some chemokines in the heart tissue of older AP may suggest a possible cardioprotective mechanism in older animals
|
118 |
Investigations into Hyperlipidemia and its Possible Associations with Pancreatitis in DogsXenoulis, Panagiotis 2011 May 1900 (has links)
The relationship between hyperlipidemia and pancreatitis remains obscure in dogs. The aim of the present study was to investigate any possible association between hyperlipidemia and pancreatitis in dogs.
In the first part of the study, Miniature Schnauzers with hypertriglyceridemia were found to have significantly higher serum cPLI concentrations than Miniature Schnauzers with normal serum triglyceride concentrations (P=0.0001). Also, Miniature Schnauzers with severe hypertriglyceridemia (>862 mg/dL) had 4.5 times higher odds (P=0.0343) for having a serum cPLI concentration consistent with pancreatitis.
In the second part of the study, 17 Miniature Schnauzers prospectively enrolled with a history of pancreatitis were significantly more likely to have hypertriglyceridemia (71 percent) after resolution of pancreatitis than 34 age-matched Miniature Schnauzers without a history of pancreatitis (33 percent; odds ratio=5.02; P=0.0163).
For the third part of the study, assessment of the feasibility and usefulness of a novel density gradient ultracentrifugation method using NaBiEDTA for lipoprotein profiling in dogs was attempted. Density gradient ultracentrifugation using NaBiEDTA was found to be useful for the study of lipoprotein profiles in dogs. Significant differences were detected in the lipoprotein profiles (mainly involving TRL and specific LDL fractions) among healthy Miniature Schnauzers, dogs of various other breeds, and hypertriglyceridemic Miniature Schnauzers.
In the fourth part of the study, the effect of a commercially available low-fat diet on serum lipid and pancreas-specific lipase (Spec cPL) concentrations and lipoprotein profiles in Miniature Schnauzers with primary hypertriglyceridemia was evaluated. The study diet was found to be effective in significantly reducing serum triglyceride and cholesterol concentrations and changing the lipoprotein profiles of the dogs studied within 2 months. However, there was no significant effect of the study diet on serum Spec cPL concentrations.
In the last part of the study, serum triglyceride and cholesterol concentrations and lipoprotein profiles were compared between dogs with naturally occurring pancreatitis and healthy dogs. The majority of dogs with naturally occurring pancreatitis had normal serum triglyceride and cholesterol concentrations. Important differences were identified in lipoprotein profiles between dogs with pancreatitis (higher LDL2, LDL3, and LDL4 fractions and lower TRL, HDL2a, and HDL3c fractions) and healthy control dogs.
|
119 |
Carboxylic ester hydrolase in acute pancreatitis : a clinical and experimental studyBlind, Per Jonas January 1994 (has links)
Diagnosis of acute pancreatitis (AP) is erroneous in up to one third of patients when based on clinical criteria and elevated serum amylase values. Furthermore, according to autopsy reports fatal pancreatitis remains clinically undiagnosed in 22 to 86 % of hospitalised patients. Consequently, search for better methods for the diagnosis of AP seems not only justified but urgent. The pancreas secretes an nonspecific lipase, the carboxylic ester hydrolase (CEH) with molecular properties different from other pancreatic secretory enzymes. These differences may imply that sites and rates of clearances from blood of pancreatic enzymes differ. Except for the pancreas this enzyme is secreted from the lactating mammary gland with milk. A sensitive and reproducible sandwich-ELISA for quantitative determination of CEH was developed. When establishing referent values it was noted that in individuals aged 20 to 65 years serum concentrations of CEH did not depend on age, gender, the time of the day or duration from food intake to blood sampling, or use of nicotine. The mammary gland did not contribute significantly to basal serum levels of CEH; enzyme levels in lactating women or women with mammary tumours were identical to those of the reference population. Seventy percent of patients with the diagnosis AP, based on elevated serum amylase levels and abdominal pain, had elevated CEH values. Among the patients with elevated amylase alone a probable cause of pancreatitis was lacking in the majority of patients. Contrastingly, a likely cause of AP could be identified in all patients presenting with abdominal pain and elevated CEH levels alone. These findings suggested that an elevated CEH level indicated AP more reliably than an elevated amylase level. In patients with AP diagnosed by contrast enhanced computed tomography (CECT) alone, or combined with histopathological diagnosis, serum CEH levels were elevated on admission in all but one patient, and in all within the next 24 h. Furthermore, in patients with severe pancreatitis CEH levels remained at a raised level from the second to at least the 10:th day following admission, whereas a significant decrease was noted in patients with mild pancreatitis. In contrast, serum amylase values were higher in patients with mild pancreatitis during the observation period than in those with severe pancreatitis. CEH levels were higher in patients with three or more Ranson signs than in those with less than three signs from the first day after admission. CEH levels were within referent range in 164 patients without known pancreatic disease admitted due to abdominal emergency conditions, or due to planned surgery for chronic extrapancreatic gastrointestinal diseases, and 16 patients having CECT without pathological findings in the pancreas. This suggests that AP can be excluded with very high degree of probability in presence of non-elevated CEH levels. A sandwich ELISA for determination of Guinea pig CEH and a model for graded pancreatitis in the same species were developed. CEH levels showed proportional to severity of inflammation, thus confirming previous clinical observations. CEH levels in bile were proportional to inflammation, while it was absent in urine. Amylase levels in urine were identical regardless of severity of inflammation, but low in bile. These results suggested differences in sites and rates of clearance between the two enzymes. Seemingly elevated CEH levels allowed identification of clinically significant pancreatitis following ERCP, which amylase levels did not. The presented studies have shown that quantitative determination in serum of CEH by the described method is a more reliable test for the diagnosis of AP than determination of amylase activity. The differences between CEH and amylase are, at least partly, due to differences in molecular properties determining rates and routes of clearances of the two enzymes from serum. / <p>Diss. (sammanfattning) Umeå : Umeå universitet, 1994, härtill 5 uppsatser.</p> / digitalisering@umu.se
|
120 |
Γονοτυπικός-φαινοτυπικός συσχετισμός στην παγκρεατίτιδαΠαπαχρήστου, Γεώργιος 31 July 2007 (has links)
Εισαγωγή: Η κλινική πορεία της οξείας παγκρεατίτιδας (ΟΠ) αντανακλά την ένταση της φλεγμονώδους αντίδρασης και ταξινομείται σε ήπια ΟΠ (ΗΟΠ) και βαριά ΟΠ (ΒΟΠ). Η έκφραση του γονιδίου της χημειοτακτικής πρωτεΐνης των μονοκυττάρων (MCP-1) επηρεάζεται από έναν A/G πολυμορφισμό (-2518) με το G αλληλόμορφο να αυξάνει την παραγωγή της MCP-1. Παχύσαρκοι ασθενείς εμφανίζουν αυξημένο κίνδυνο για επιπλοκές από ΟΠ. Το σύστημα APACHE-O έχει προταθεί ότι βελτιώνει την ακρίβεια του συστήματος APACHE-ΙΙ στην πρόγνωση της ανάπτυξης ΒΟΠ.
Στόχοι: 1) Να διευκρινίσουμε αν ο πολυμορφισμός στο γονίδιο της MCP-1 στη θέση -2518 επηρεάζει την βαρύτητα της ΟΠ, 2) αν το σύστημα APACHE-O βελτιώνει την προγνωστική αξία του συστήματος APACHE-ΙΙ και 3) να διερευνήσουμε την υπόθεση ότι οι παχύσαρκοι ασθενείς βρίσκονται σε αυξημένο κίνδυνο για την ανάπτυξη ΒΟΠ λόγω της μεγαλύτερης φλεγμονώδους απόκρισης που παρουσιάζουν στην παγκρεατική προσβολή.
Μέθοδοι: Μελετήθηκαν 102 ασθενείς με ΟΠ και 116 άτομα αποτέλεσαν την ομάδα των υγιών μαρτύρων. Ο A/G γονότυπος της MCP-1 ανιχνεύθηκε με την μέθοδο της αλυσιδωτής αντίδρασης της πολυμεράσης και με προσδιορισμό της αλληλουχίας του DNA. Τα επίπεδα της MCP-1 στον ορό μετρήθηκαν με φθορίζουσα ανοσολογική μέθοδο. Υπολογίσθηκαν οι καμπύλες ROC των συστημάτων APACHE-II και APACHE-O. Η παχυσαρκία και άλλες κλινικές παράμετροι εκτιμήθηκαν ως παράγοντες κινδύνου για την ανάπτυξη ΒΟΠ με τη χρήση ανάλυσης λογισμικής παλινδρόμησης. Συγκρίναμε τα επίπεδα των IL-6, MCP-1 και CRP στον ορό και των κριτηρίων του Ranson σε παχύσαρκους και μη-παχύσαρκους ασθενείς με ΟΠ.
Αποτελέσματα: 19 ασθενείς ανέπτυξαν ανεπάρκεια οργάνων και ταξινομήθηκαν ως ΒΟΠ. Οι ασθενείς με ΒΟΠ βρέθηκαν να έχουν σημαντικά υψηλότερο ποσοστό του G αλληλομόρφου (86%) σε σχέση με τους ασθενείς με ΗΟΠ (46%) (p<0,007). Οι ασθενείς με ΒΟΠ είχαν επίσης υψηλότερα επίπεδα της MCP-1 στον ορό σε σχέση με τους ασθενείς με ΗΟΠ (p=0,002). Το 28% των ασθενών ήταν παχύσαρκοι (BMI >30). Τα συστήματα APACHE-O (AUC: 0,895) και APACHE-ΙΙ (AUC: 0,893) έδειξαν παρόμοια ακρίβεια στην πρόγνωση της ανάπτυξης ΒΟΠ. Η παχυσαρκία βρέθηκε να αποτελεί παράγοντα κινδύνου για την ανάπτυξη ΒΟΠ (OR: 2,8, p=0,048) και θνητότητας (OR: 11,2, p=0,022). Τα επίπεδα της CRP (p=0,0001) και τα κριτήρια Ranson (p=0,021) βρέθηκαν σημαντικά υψηλότερα στους παχύσαρκους ασθενείς. Τα επίπεδα των IL-6 και MCP-1 βρέθηκαν υψηλότερα στους παχύσαρκους ασθενείς, χωρίς όμως να είναι στατιστικώς σημαντικά.
Συμπεράσματα: Το -2518 G αλληλόμορφο της MCP-1 αποτελεί παράγοντα κινδύνου για την ανάπτυξη ΒΟΠ. Τα επίπεδα της MCP-1 δείχνουν να αποτελούν ακριβή προγνωστικό δείκτη για την ανάπτυξη ΒΟΠ και θανάτου. Η παχυσαρκία αποτελεί επίσης ανεξάρτητο παράγοντα κινδύνου για την ανάπτυξη ΒΟΠ. Το σύστημα APACHE-O κατά την εισαγωγή των ασθενών δεν είναι πιο ακριβές από το σύστημα APACHE-ΙΙ. Τα αποτελέσματα της μελέτης μας προτείνουν ότι η παχυσαρκία αυξάνει την βαρύτητα της ΟΠ λόγω της μεγαλύτερης ανοσολογικής απόκρισης στην παγκρεατική προσβολή. / Background: Acute pancreatitis (AP) reflects the intensity of the inflammatory response and is divided into mild AP (MAP) or severe AP (SAP). Monocyte chemotactic protein-1 (MCP-1) gene expression is altered by an A/G polymorphism (-2518), with the G allele increasing MCP-1 production. Obese patients appear to be at risk for complications of AP. APACHE-O score has been suggested to improve APACHE-II accuracy in predicting severe outcome in AP.
Aims: Τo determine whether: 1) the MCP-1 −2518 A/G polymorphism affects the severity of AP, 2) if APACHE-O score adds any predictive value to APACHE-II score and 3) to test the hypothesis that obese patients are at increased risk of SAP because of a more intense inflammatory response to pancreatic injury.
Methods: 102 consecutive AP patients and 116 controls were evaluated. The A/G genotype was evaluated by polymerase chain reaction amplification and DNA sequencing. MCP-1 serum levels were quantified using a fluorescence bead-based immunoassay. Receiver operating curves (ROC) for prediction of SAP were calculated using admission APACHE-II and APACHE-O scores. Binary logistic regression was performed to assess if obesity is a risk for SAP and to determine the clinical factors associated with severe disease. Serum levels of IL-6, MCP-1 and CRP as well as Ranson’s scores were compared between obese and non-obese patients.
Results: Nineteen patients developed organ dysfunction and were classified as SAP. Patients with SAP had a significantly greater proportion of the G allele (86%) than did MAP patients (46%) (p<0.007). As predicted by the genotype, the serum MCP-1 levels were significantly higher in the SAP patients when compared with the MAP patients (p=0.002). Using a body mass index (BMI) >30, 28% of the subjects were obese. Admission APACHE-O (Area under the curve AUC: 0.895) and APACHE-II (AUC: 0.893) showed similar accuracy in predicting severe outcome. BMI>30 was identified as a significant risk for SAP (OR: 2.8, p=0.048) and mortality (OR: 11.2, p=0.022). CRP levels were significantly higher in obese AP patients (p=0.0001) as well as Ranson’s score (p=0.021). IL-6 and MCP-1 levels were higher in obese patients but did not reach statistical significance.
Conclusions: MCP-1 −2518 G allele is a risk factor for severe AP. MCP-1 serum levels, measured early in the course of AP, appear to be an accurate predictor of severity of acute pancreatitis and death. Obesity is an independent risk for severe acute pancreatitis. Admission APACHE-O score is not more accurate than APACHE-II score. Our study results suggest that obesity increases the severity of AP by amplifying the immune response to injury.
|
Page generated in 0.0474 seconds